Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Edaravone
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Specialised Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Treeway Licensing Deal with Specialised Therapeutics
Details : Under the licensing agreement, ST will be responsible for all marketing, regulatory and distribution activities of TW001, a unique oral formulation of edaravone which works by reducing the oxidative damage associated with neuron death in ALS, in Australi...
Brand Name : TW001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 28, 2023
Lead Product(s) : Edaravone
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Specialised Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
